This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Abraham, J. Search for Related Content Social Bookmarking                         What's this?

Distributing the Benefit of the Doubt: Scientists, Regulators, and Drug Safety

University of Reading, United Kingdom

This article examines how scientists and regulators distribute the benefit of the doubt about drug safety under conditions of scientific uncertainty. The focus of the empirical research is the regulatory controversy over the hepatorenal toxicity of benoxaprofen in the United Kingdom and the United States. By scrutinizing the technical coherence of the arguments put forward by industrial and government scientists, it is concluded that these scientists are willing to award the commercial interests of the pharmaceutical industry an enormous benefit of the sccentific doubt, which is not consistent with the best interests of patients. Interpretative flexibility, the burden of proof falling on regulators and their trust in, and dependence on, industrial scientists facilitates that distribution of the benefit of the scientific doubt. However, regulatory authorities' need for viability and the rationality common to opposing scientific views suggest that it is possible, in principle, to alter this dominant trend. To achieve adequate patient protection, drug regulation in the United Kingdom and the United States requires extensive reform. Some preliminary policy changes are sketched.

Science, Technology & Human Values, Vol. 19, No. 4, 493-522 (1994)
DOI: 10.1177/016224399401900404


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L McGoey and E Jackson Seroxat and the suppression of clinical trial data: regulatory failure and the uses of legal ambiguity J. Med. Ethics, February 1, 2009; 35(2): 107 - 112. [Abstract] [Full Text] [PDF]

				G. Edmond The Law-Set: The Legal-Scientific Production of Medical Propriety Science Technology Human Values, April 1, 2001; 26(2): 191 - 226. [Abstract] [PDF]

				S. Epstein The Construction of Lay Expertise: AIDS Activism and the Forging of Credibility in the Reform of Clinical Trials Science Technology Human Values, October 1, 1995; 20(4): 408 - 437. [Abstract] [PDF]